Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 238

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 238
---
.

The restated consolidated balance sheet line items for the third fiscal quarter of 2023 are as follows:

Schedule of Quarterly Financial Data

|                                |     | As Reported | September 30, 2023 |   |     | Adjustments | September 30, 2023 |   |     | Restated | September 30, 2023 |   |
|:-------------------------------|:----|:------------|-------------------:|:--|:----|:------------|-------------------:|:--|:----|:---------|-------------------:|:--|
| Additional paid in capital (1) |     |             |         19,456,841 |   |     |             |          9,945,692 |   |     |          |         29,402,533 |   |
| Accumulated deficit            |     |             |        (13,847,112 | ) |     |             |         (9,945,692 | ) |     |          |        (23,792,804 | ) |

| (1) | The                                                                                       
 Reverse Stock Split (Note 1) also resulted in an adjustment to the condensed consolidated 
 balance sheet for the period ended September 30, 2023 with an increase to additional paid 
 in capital of $140 and an offsetting adjustment to the carrying value of common stock.    |

The adjustments did not have an effect on the consolidated
statement of operations or cash flows for the three fiscal quarters of 2023.

The Company has included its restated quarterly unaudited
consolidated financial information for the interim periods ended March 31, 2023 and June 30, 2023 within Form 10-Q/A for the period ended
March 31, 2024 and Form 10-Q for the period ended June 30, 2024, respectively, filed concurrent with this Form 10-K/A.

| F-45 |

Note 12 – Subsequent Events

Management evaluated all additional events subsequent to the balance sheet date through the date the consolidated financial statements were issued and determined that the following items are required to be disclosed.

Restatement of Previously Issued Financial Statements

See Note 2.

Nasdaq Bid Price Requirement Extension Granted until August 26, 2024

On August 31, 2023, after the Company’s common stock had traded below $ 1.00per share for 30consecutive trading days, the Company received notice from the Nas